Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy

Table 1 Clinicopathological characteristics of Siewert type II adenocarcinoma of the esophagogastric junction underwent radical gastrectomy with neoadjuvant chemotherapy

Characteristics	n (%)/mean ± SD
Age, (yr)
< 65	468 (64.6)
≥ 65	257 (35.4)
Sex
Male	623 (85.9)
Female	102 (14.1)
Marital status
Married	502 (69.2)
Divorced or separated	79 (10.9)
Single (never married)	91 (12.6)
Widowed	30 (4.1)
Others	23 (3.2)
Race
White	647 (89.2)
Others	78 (10.8)
Year of operation
2004-2009	230 (31.7)
2010-2015	495 (68.3)
Type of surgery
Subtotal gastrectomy	418 (57.7)
Total gastrectomy	156 (21.5)
Unknown	151 (20.8)
Tumor size
< 50 mm	387 (53.4)
≥ 50 mm	200 (27.6)
Unknown	138 (19.0)
The number of examined lymph nodes	17.4 ± 10.9
yp T stage
T1	82 (11.3)
T2	108 (14.9)
T3	441 (60.8)
T4	94 (13.0)
yp N stage
N0	218 (30.1)
N1	223 (30.8)
N2	186 (25.7)
N3	98 (13.5)
Grade
Well differentiated	35 (4.8)
Moderate differentiated	253 (34.9)
Low differentiated	400 (55.2)
The tumor grade cannot be identified	37 (5.1)
Adjuvant chemotherapy
No	530 (73.1)
Yes	139 (19.2)
Unknown	56 (7.7)